A Study of ONO-7018 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Summary

ONO-7018 is a selective inhibitor of mucosa associated lymphoid tissue protein 1 (MALT1) and is expected to exhibit antitumor activity in NHL. This study is Phase1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (biomarkers) and efficacy of ONO-7018 in patients with relapsed or refractory NHL.

Timeline

Start

2024-11-27

Primary completion

2027-07-31

Completion

2029-12-31

Drugs

Indications